Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
959.9 USD | -0.47% | -0.47% | +9.29% |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.29% | 104B | B+ | ||
+1.10% | 105B | B+ | ||
-3.00% | 22.09B | B | ||
-11.89% | 21.98B | B+ | ||
-26.59% | 20.17B | A- | ||
-5.20% | 19.49B | A- | ||
-6.58% | 17.75B | B | ||
+5.83% | 13.84B | C+ | ||
+7.46% | 11.64B | D | ||
+28.56% | 11.55B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Regeneron Pharmaceuticals, Inc. - Nasdaq
- Ratings Regeneron Pharmaceuticals, Inc.